Abstract
Several types of cancer have been shown to be susceptible to cellular immune responses, leading to investigations using various forms of T cell-based, tumor-directed immunotherapy. One potential obstacle for the successful application of these therapies is the suppressive function of Tregs. Goldstein and colleagues evaluate a strategy to identify and remove Tregs from an adoptive T-cell therapy product generated by in vivo vaccination. They demonstrate that the depletion of Tregs characterized by CD44 and CD137 expression enhances antitumor immunity in their mouse model.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Biomarkers / metabolism
-
Cell Separation
-
Flow Cytometry
-
Humans
-
Hyaluronan Receptors / metabolism
-
Immunotherapy, Adoptive*
-
Lymphocyte Depletion*
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / therapy*
-
Mice
-
Mice, Inbred C57BL
-
Radiation Chimera
-
T-Lymphocyte Subsets / immunology*
-
T-Lymphocytes / transplantation*
-
T-Lymphocytes, Regulatory / immunology*
-
Tumor Necrosis Factor Receptor Superfamily, Member 9 / metabolism
Substances
-
Biomarkers
-
Hyaluronan Receptors
-
Tumor Necrosis Factor Receptor Superfamily, Member 9